Clinical trial · Interventional
18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme
NCT04588454CI-TRIAL-00049675PSMA-GBMunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot study to determine uptake of PET tracer 18F-PSMA-1007 in primary glioblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-PSMA-1007 PET tracer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-PSMA-1007 PET/CT
- interventionNames
- Other: 18F-PSMA-1007 PET tracer
Primary outcomes (1)
- measure
- The uptake of 18F-PSMA PET/CT in suspected GBM lesions
- timeFrame
- uptake of the tracer at 2 hours post injection
Secondary outcomes (2)
- measure
- The correlation between PSMA protein and RNA expression with 18F-PSMA PET/CT uptake
- timeFrame
- uptake of the tracer at 2 hours post injection vs RNA expression determined from excised tumor tissue
- measure
- Correlation between 18F-PSMA PET/CT and T1Gd MRI
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspected GBM on MRI scan * Scheduled for tumor resection at Radboudumc * Age ≥18 years Exclusion Criteria: * Age \< 18 years * Pregnancy or the wish to become pregnant within 6 months * Creatinine clearance below 40ml/min * Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
References
Publications (1)
- DERIVEDMcBriar JD, Shafiian N, Scharf S, Boockvar JA, Wernicke AG. Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future. Clin Nucl Med. 2024 Sep 1;49(9):806-816. doi: 10.1097/RLU.0000000000005365. Epub 2024 Jul 1. PMID 38968568